Hannah R. Abrams

@hannahrabrams.bsky.social

2318 Followers 404 Following

Sarcoma doctor at Fred Hutch, hoping to make rare cancer research easier & more efficient for patients/caregivers. Social Media Editor @ JCO OP. Views are my own. #MedSky

Information page for Isochrones API.The Isochrones API calculates the area that a person can reach from a specific origin point within a set amount of time. Unlike a radius, which measures a straight-line distance, an isochrone accounts for actual road network travel times to create a polygon that represents true reachability. Common use cases include: Delivery logistics: Determine which customers are servable within 30 minutes of a warehouse. Real estate: Find properties within a 45-minute commute of a workplace. Urban planning: Analyze the accessibility of essential services like hospitals or grocery stores. To get started, see Set up the Isochrones API.
Fig 2. (A) TAT intervals and definitions. (B) and (E) Yearly NSCLC CGP TAT and trend analysis (2018-2024). Boxes indicate median TAT, and whiskers indicate IQR. Dotted lines are linear trendlines: (B) overall TAT [Y = –1.154 × X + 2,361.0], (C) ordering TAT [Y = 0.2143 × X – 419.5], (D) specimen TAT [Y = –0.1357 × X + 279.0], and (E) molecular TAT [Y = –1.079 × X + 2,190.0]. P values reflect linear regression analysis (*P < .05, **P < .01, ***P < .001). CGP, comprehensive genomic profiling; NSCLC, non–small cell lung cancer; TAT, turnaround time.
Impact of corticosteroid exposure on long-term immune checkpoint in- hibitor responses in solid tumors. First Author: Theresa Medina, University of Colorado, Aurora, CO. Text beyond allowed length; summary: The steroid exposure was defined as very high if prednisone (or equivalent) ≥ 20mg/day and length of exposure was ≥ 42 days. 64.8% of patients experienced an irAE and 44.7% of patients developed G3-4 irAE requiring corticosteroids +/- steroid sparing agent. The low impact corticosteroid exposure did not affect PFS, OS or tumor specific survival. The very high impact CS exposure was associated with decrease in PFS (p = 0.02) but not with OS or TSS (p = 0.3). The high impact steroid sparing agent was associated with decrease in PFS (not significant) but the very high impact steroid sparing agent was associated with decrease in PFS. The chronic irAE was associated with slight improvement in PFS (not significant).
Fig 2. Kaplan-Meier analysis of time to ACM in the (A) overall population, (B) patients with the kappa isotype, and (C) patients with the lambda isotype. Censor events are shown by vertical tick marks. ACM, all-cause mortality; PCD, plasma cell dyscrasia.
Inadvertent Dose Reduction of Chemotherapy in a Patient Receiving Multiagent Neoadjuvant Chemotherapy Authors: Ruth E. Choa, MD, PhD https://orcid.org/0000-0002-4798-7565 ruth_choa@dfci.harvard.edu, Kevin H. Lin, MD, PhD, Matthew L. Meizlish, MD, PhD https://orcid.org/0000-0002-4306-5061, Christof C. Smith, MD, PhD https://orcid.org/0000-0001-6517-0439, Katherine J. Feder, MD, MS, and Joseph O. Jacobson, MD, MSc
Title of article: 340B Drug Pricing Program: An Updated ASCO Policy Statement Authors: Blase Polite, MD, MPP, FASCO 1 ; Niharika Dixit, MD 2 ; John Hennessy, BCPA 3 ; Marissa Rivera, MBA 4 ; Ashley Sumrall, MD, FACP, FASCO 5 ; Wade Swenson, MD, MPH, MBA, FACP 6 ; Kashyap Patel, MD 7 ; Natalie Dickson, MD, MMHC, FACP 8 ; Jonathan Phillips, MPH 9 ; Azam Masood, MPH 9 ; and Allyn Moushey, MSW 9
Title page and abstract: Cost-Effectiveness of Maintaining Higher Stem-Cell Collection Thresholds in the Chimeric Antigen Receptor T-Cell Era for Multiple Myeloma Ehsan Malek, MD 1 ; Brian Betts, MD 1 ; Megan Herr, PhD 1 ; Marco Davila, MD 1 ; Shernan Holtan, MD 1 ; James J. Driscoll, MD, PhD 2,3 ; and Han Yu, PhD 1
Table 3. Practice Implications for Oncology Providers in Low-Broadband Settings Practice Domain Key Implication Proactive Offering Proactively offer VTVs even in low-broadband regions; patients may adopt VTV when given the option Modality Matching Reserve in-person care for essential physical examinations, labs, transfusions, or imaging, while offering VTV for follow-ups, counseling, and routine check-ins Situational Flexibility Frame VTV as a safe and practical alternative, especially, during adverse weather, long travel distances, or out-of-state circumstances Digital Readiness Build digital comfort through low-stakes trial runs, patient portal tutorials, or staff-led technology coaching to reduce first-visit barriers Relational Care Validate patients' preference for face-to-face care while emphasizing strategies to maintain connection, attention, and trust during VTV Future Planning Normalize VTV as a scalable option that patients may increasingly rely on with aging, mobility limitations, or worsening weather conditions
TABLE 2. Participant-Reported Measures: Prognostic Perceptions and Hope at the Time of Phase I Clinical Trial Enrollment 27.4% report goal of cancer treatment is to cure cancer, 40% describe themselves as not terminally ill, and 37.8% report never or rarely discussing prognosis with oncologist.
Title: Economics of Translating Research Into Practice: The Case of Exercise to Prevent Cancer Recurrence Allan S. Detsky, MD, PhD 1,2,3 ; Kerry S. Courneya, PhD 4 ; Christopher M. Booth, MD 5 ; and Shivan J. Mehta, MD, MBA, MSHP 6,7
Fig 2. Medicare projected versus actual utilization of G2211. All physicians were anticipated to report 83.7 million uses of the code but only reported 24.7. Hematology/oncology physicians expected to report 3.2 million but only reported 1.6 million.
Fig 1. Reference characteristics to the article by Ross et al by year of publication. Stacked area chart depicting the distribution of citation characteristics referencing the article by Ross et al, categorized by publication year (2010-2025). Each color represents a distinct citation characteristic: Affirmative, contrastive, assumptive, conceptual, methodologic, perfunctory, and negative. Vertical dashed lines mark two key regulatory events: the 2011 cisplatin label update and the 2015 label revision.
FIG 1. The inferred relationships between theme components.
Fig A3. Improvements in efficiency of care by age.
Fig 1. Association of donor age with OS. (A) The plot shows the unadjusted HR for death according to donor age. A linear model (red line) is compared with a more flexible spline model (blue line), which allows for a non-linear relationship. Shaded ribbons represent 95% CIs. The similarity between the two models and the fact that their CIs consistently overlap an HR of 1.0 indicates that there is no significant linear or nonlinear association between donor age and survival in this cohort. (B) Kaplan-Meier analysis of OS stratified by dichotomized donor age: donors younger than 32 years (red) versus those 32 years and older (blue). There was no statistically significant difference in survival between the two groups (log-rank P = .51). HR, hazard ratio; OS, overall survival.
Fig 2. Constraints related to the patient, the pharmacy, and the outpatient infusion centers to be taken into account when concentrating outpatient ICI administrations in a stipulated time window in the morning. ICI, immune checkpoint inhibitor. Pharmacy constraints: physiochemical stability, risk of waste. Patient: distance home-hospital, diurnal preference. Day unit: priority rankings, long multi drug regimens.
Fig 1. (A and B) Thirty- and 90-day outcomes of intended complete treatment with histotripsy by histologic tumor treated and (C) time-to-event analysis for primary versus secondary malignancy. CCA, cholangiocarcinoma; CRLM, common cancer, with liver metastasis; HCC, hepatocellular carcinoma; HNSC, head and neck squamous cell; NET, neuroendocrine tumor; PDAC, pancreatic ductal adenocarcinoma.
Image of Victor Wembanyama, star of the San Antonio Spurs, over an image of a burr cell
At first glance, Collineau's findings seem to be predictable: FOLFIRINOX is toxic, and OAs are vulnerable. But the deeper issue is whether we are asking the right question. By focusing narrowly on which OA can endure FOLFIRINOX, we risk missing the more relevant point: what is the most tolerable approach to the care of OAs with PDAC, and who truly benefits? The Edison analogy is instructive here. His lasting legacy was not the brightest bulb, but the system that made light usable, safe, and enduring. In PDAC, the lesson is similar: the discovery of an intense regimen is useless unless it is embedded in a system that makes treatment tolerable and meaningful for patients. For OAs, that grid is built through geriatric assessment (GA), supportive interventions (nutrition, prehabilitation, psychosocial support), and integration of palliative care.
At a measured GFR of 45, corresponding eGFR values ranged from 53 to 59 mL/min/1.73 m2
Table of employment and financial support recommendations from survivors by time period. Across the care continuum: Consider jobs that cover financial and insurance needs Set up a health savings account, contribute a small amount from each paycheck to help pay medical bills Ask for help from the care team, especially hospital social worker and use hospital billing department regarding cancer-related finances and resources Seek college scholarships During active therapy Explore short-term disability or other benefits offered by employer Consider ways to cut nonmedical expenses Seek financial assistance grants Set up a payment plan Learn/connect with other YAs on how they handled finances and cancer Early in survivorship Maintain employment with stable health insurance coverage Build financial literacy Seek vocational counseling to mitigate cancer-related job impacts Save money to account for rising cost of living and possible future medical costs
Table 2: Likelihood of Spend-Down Among Individuals Initially Non-Medicaid Enrolled by Demographic Characteristics and Length of Nursing Home Stay Highlighted statistic showing that at 4 years after index nursing home stay, Black individuals have a 72.3% predicted probability of having undergone a spend down (difference 0.11, 95% CI 0.05-0.17), as compared to 61.2% for White individuals.
Fig 1. Phases of cancer survivorship, graphic created by the National Cancer Institute. The central ovals represent the anatomic extent of disease (ie, stage of a cancer). The ovals are encircled by a loop that denotes the corresponding goals of care. The bidirectional arrows within the loop illustrate the dynamic nature of goals of care. Over time because of changes in their cancer status, survivors may transition between different phases of survivorship, with corresponding shifts in their goals of care. Notably, the central section in the figure represents the population of interest: survivors with advanced and metastatic cancer for whom the goal of care is to prolong life.
Slide on what caregivers are doing during the transplant/CAR T process. Roles include fever monitoring, meal prep & encouragement, emotional support, transportation to appointments, blood pressure & symptom checks, cleaning, (complex!) medication management, financial support & childcare. Caption beneath the slide reads "In a 25 minute talk, it might have been easier to ask what the caregivers *aren't* doing"
Slide from National Alliance for Caregiving presentation of data. Ranking of top barriers by modality for auto HCT, allo HCT, and CAR T. For all 3, caregiving is #1 barrier and local housing #2. #3 is cost & other caregiving duties for auto HCT, cost for allo HCT, and insurance coverage for CAR T.
Definition of local housing (distance to center) at different CAR T centers. 28% require patients within 30 minutes, 41% within 60 minutes, and 21% within 120 minutes.
Figure 2. Figure 2. Local housing requirement for auto HCT (A/B), allo HCT (C/D), and CAR T-cell therapy (E/F). * Denotes 1 institution that reported a requirement of within 30 minutes for until day 14, then within 2 hours until day 28.“Other” responses by modality: Auto HCT - within 45 minutes; Allo HCT - within 45. Range between 30 and 120 minute requirements for all modalities and similar ranges in local housing days. The median (range) of days required by modality was 30 (3-100) for auto HCT, 100 (28-100) for allo HCT, and 30 (14-56) for CAR T-cell therapy. Centers reporting a multistate catchment area (n = 14) had a slightly lower median day require- ment at 20.5 (3-100) for auto HCT, 75 (30-100) for allo HCT, and 30 (28-30) for CAR T.
For auto transplant only 81% of centers allowed paid caregivers; for allo transplant 77%; and for CAR T 81%.
Histogram of days required for autologous HCT. Range from 14-107 days.
Magazine paragraph with highlighted passage: Men's risk rises with "a strong family history of breast cancer," says Dr. Christine Brezden-Masley, senior practicing medical oncologist at Sinai Health System in Toronto and a Costco member. "If your mother, her mother and your sister has or had breast cancer, you may have a genetic predisposition toward it."
Map of gabapentin regulatory status. States which have both scheduling and PDMP requirements for gabapentin are ND, UT, KY, WV, VA, TN, AL
Figure 1. Distribution and Median Smoking Pack-Years at Diagnosis by Race for Incident Lung Cancer Cases. Both figures show higher incidence of lung cancer in lower pack-year distribution for African American people compared to White people.
Highlighted passage: Included in this study were patients with biopsy-confirmed mNSCLC who had not yet progressed or experienced serious adverse events to single-agent chemotherapy, and thus had reasonable options for further palliative systemic therapy. Patients must have been discharged to a SNF with an intention for further therapy once functional status permitted.